Literature DB >> 22465296

Bryostatin analogue-induced apoptosis in mantle cell lymphoma cell lines.

Ana Lopez-Campistrous1, Xiaohua Song, Adam J Schrier, Paul A Wender, Nancy A Dower, James C Stone.   

Abstract

The anti-cancer effects of bryostatin-1, a potent diacylglycerol analogue, have traditionally been attributed to its action on protein kinase C. However, we previously documented apoptosis in a B non-Hodgkin lymphoma cell line involving diacylglycerol analogue stimulation of Ras guanyl-releasing protein, a Ras activator, and Bim, a proapoptotic Bcl-2 family protein. To further explore the role of Bim, we examined several Bim-deficient B non-Hodgkin lymphoma cells for their responses to pico, a synthetic bryostatin-1-like compound. The Bim(-) mantle cell lymphoma cell lines Jeko-1, Mino, Sp53, UPN1, and Z138 and the Bim(+) cell line Rec-1, as well as the Burkitt lymphoma cells lines BL2 (Bim(-)) and Daudi (Bim(+)), were examined for their response to pico using assays for proliferation and apoptosis as well as biochemical methods for Ras guanyl-releasing proteins and Bcl-2 family members. With the exception of UPN1, mantle cell lymphoma cell lines underwent pico-induced apoptosis, as did BL2. In some cases, hallmarks of apoptosis were substantially diminished in the presence of mitogen-activated protein kinase kinase inhibitors. Pico treatment generally led to increased expression of proapoptotic Bik, although the absolute levels of Bik varied considerably between cell lines. A pico-resistant variant of Z138 exhibited decreased Bik induction compared to parental Z138 cells. Pico also generally decreased expression of anti-apoptotic Bcl-XL and Mcl1. Although, these changes in Bcl-2 family members seem unlikely to fully account for the differential behavior of the cell lines, our demonstration of a potent apoptotic process in most cell lines derived from mantle cell lymphoma encourages a re-examination of diacylglycerol analogues in the treatment of this subset of B non-Hodgkin lymphoma cases.
Copyright © 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22465296      PMCID: PMC4059058          DOI: 10.1016/j.exphem.2012.03.002

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  27 in total

1.  The practical synthesis of a novel and highly potent analogue of bryostatin.

Authors:  Paul A Wender; Jeremy L Baryza; Chad E Bennett; F Christopher Bi; Stacey E Brenner; Michael O Clarke; Joshua C Horan; Cindy Kan; Emmanuel Lacôte; Blaise Lippa; Peter G Nell; Tim M Turner
Journal:  J Am Chem Soc       Date:  2002-11-20       Impact factor: 15.419

Review 2.  Role of Bim and other Bcl-2 family members in autoimmune and degenerative diseases.

Authors:  Peter Hughes; Philippe Bouillet; Andreas Strasser
Journal:  Curr Dir Autoimmun       Date:  2006

Review 3.  What do we know about the mechanisms of elimination of autoreactive T and B cells and what challenges remain.

Authors:  Andreas Strasser; Hamsa Puthalakath; Lorraine A O'Reilly; Philippe Bouillet
Journal:  Immunol Cell Biol       Date:  2007-11-20       Impact factor: 5.126

4.  RasGRP, a Ras guanyl nucleotide- releasing protein with calcium- and diacylglycerol-binding motifs.

Authors:  J O Ebinu; D A Bottorff; E Y Chan; S L Stang; R J Dunn; J C Stone
Journal:  Science       Date:  1998-05-15       Impact factor: 47.728

Review 5.  Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics.

Authors:  Annette S Gillings; Kathryn Balmanno; Ceri M Wiggins; Mark Johnson; Simon J Cook
Journal:  FEBS J       Date:  2009-09-29       Impact factor: 5.542

6.  RasGRP links T-cell receptor signaling to Ras.

Authors:  J O Ebinu; S L Stang; C Teixeira; D A Bottorff; J Hooton; P M Blumberg; M Barry; R C Bleakley; H L Ostergaard; J C Stone
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

7.  Regulation and Function of the RasGRP Family of Ras Activators in Blood Cells.

Authors:  James C Stone
Journal:  Genes Cancer       Date:  2011-03

8.  Mutations of the BIK gene in human peripheral B-cell lymphomas.

Authors:  Vincenzo Arena; Maurizio Martini; Myriam Luongo; Arnaldo Capelli; Luigi Maria Larocca
Journal:  Genes Chromosomes Cancer       Date:  2003-09       Impact factor: 5.006

9.  Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3.

Authors:  Bingzhen Lin; Siva Kumar Kolluri; Feng Lin; Wen Liu; Young-Hoon Han; Xihua Cao; Marcia I Dawson; John C Reed; Xiao-kun Zhang
Journal:  Cell       Date:  2004-02-20       Impact factor: 41.582

10.  Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas.

Authors:  Cinta Mestre-Escorihuela; Fanny Rubio-Moscardo; Jose A Richter; Reiner Siebert; Joan Climent; Vicente Fresquet; Elena Beltran; Xabier Agirre; Isabel Marugan; Miguel Marín; Andreas Rosenwald; Kei-Ji Sugimoto; Luise M Wheat; E Loraine Karran; Juan F García; Lydia Sanchez; Felipe Prosper; Louis M Staudt; Daniel Pinkel; Martin J S Dyer; Jose A Martinez-Climent
Journal:  Blood       Date:  2006-09-07       Impact factor: 22.113

View more
  3 in total

Review 1.  Protein kinase C in cancer: The top five unanswered questions.

Authors:  Mariana Cooke; Andrew Magimaidas; Victoria Casado-Medrano; Marcelo G Kazanietz
Journal:  Mol Carcinog       Date:  2017-03-10       Impact factor: 4.784

2.  RasGRPs are targets of the anti-cancer agent ingenol-3-angelate.

Authors:  Xiaohua Song; Ana Lopez-Campistrous; Lucy Sun; Nancy A Dower; Noemi Kedei; Jing Yang; Jessica S Kelsey; Nancy E Lewin; Tim E Esch; Peter M Blumberg; James C Stone
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

3.  RAS at the Golgi antagonizes malignant transformation through PTPRκ-mediated inhibition of ERK activation.

Authors:  Berta Casar; Andrew P Badrock; Iñaki Jiménez; Imanol Arozarena; Paula Colón-Bolea; L Francisco Lorenzo-Martín; Irene Barinaga-Rementería; Jorge Barriuso; Vincenzo Cappitelli; Daniel J Donoghue; Xosé R Bustelo; Adam Hurlstone; Piero Crespo
Journal:  Nat Commun       Date:  2018-09-05       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.